Switching from Semaglutide to Tirzepatide: How the Transition Actually Works

Step 1: Understand what you're actually moving between

Semaglutide works on one receptor, the GLP-1 pathway, slowing gastric emptying and reducing appetite. Tirzepatide does the same, but also activates the GIP receptor, making it the only dual-agonist weight-loss medicine licensed in the UK. That second pathway is thought to contribute to the greater average weight loss seen in trials. In the SURMOUNT-5 head-to-head study, published in the New England Journal of Medicine (2025), tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. That finding matters when you're weighing up whether a switch might be worthwhile, but it doesn't mean tirzepatide suits everyone who didn't reach their goal on semaglutide. There are other variables, including tolerability, other medicines you take, and your medical history. That context is exactly what a prescriber reviews.

For a plain side-by-side of the two medicines before you go further, our Wegovy vs Mounjaro comparison covers the licensed indications, trial results and practical differences in one place.

Step 2: The clinical assessment that has to happen before anything changes

Switching is not like changing a broadband provider. Because both medicines are prescription-only, the prescriber needs to review your current dose, how long you've been on it, what weight loss you've achieved, and whether any side effects have been an issue. They will also check for contraindications to tirzepatide that might not have been relevant with semaglutide — for instance, if you are using oral contraceptives, MHRA guidance advises adding a non-oral method for the first four weeks of tirzepatide and for four weeks after each dose increase, because absorption of the pill may be affected. That doesn't apply in the same way with semaglutide, so it's a new clinical consideration a prescriber must raise. NHS England's guidance on weight-management injections covers this and other practical points for people on GLP-1 treatment.

At nume, every consultation (including transfer requests and dose or product changes) is read by a named prescriber, not a queue managed by automation. If you're already on semaglutide elsewhere, our team can review evidence of your current treatment as part of that process. The eligibility details for switching from semaglutide to tirzepatide are worth reading before you start.

Step 3: What the evidence says about results, honestly stated

A comparison between semaglutide and tirzepatide on average weight-loss figures shows a consistent picture in trials, but averages hide a lot. Some people do very well on semaglutide 2.4mg; others plateau. The STEP 1 trial reported roughly 15% average body-weight reduction at 68 weeks for semaglutide 2.4mg, as published in the NEJM. SURMOUNT-1 reported around 20 to 21% at 15mg tirzepatide. NICE's appraisal of tirzepatide (TA1026) notes that indirect comparisons favour tirzepatide, and the head-to-head SURMOUNT-5 data confirmed that. The table below sets out the key factual differences.

Which result is achievable for you is something a prescriber can only estimate in context. People who plateaued at a lower semaglutide dose may respond differently at a higher one; others may find the dual mechanism of tirzepatide produces a meaningful step forward. Neither outcome is certain in advance. If you're trying to decide whether the two medicines are close enough to be interchangeable, our page on how similar Mounjaro and Wegovy actually are sets out the key differences in a way that's useful before you commit to a switch.

Step 4: Practical things to know before you switch

Tirzepatide starts at 2.5mg. That first pen's purpose is to let your system adjust, not to deliver the full therapeutic effect, so people transferring from semaglutide sometimes find the early weeks feel like a step back. Nausea, stomach discomfort and loose stools are possible as with any GLP-1, and they tend to be most noticeable in the first two weeks after a dose change. Starting from 2.5mg even if you've been on a high dose of semaglutide is generally how the titration begins, though your prescriber determines the schedule based on your history.

Storage: tirzepatide pens are refrigerated at 2 to 8°C. For the exact room-temperature window the pen can be outside the fridge, always check the Patient Information Leaflet — the figures differ by product and pen age, and this is one detail worth getting right. Our practical guide to moving from semaglutide to tirzepatide covers the logistics of the first weeks in more detail. If you're currently on Mounjaro and considering the direction of travel in reverse, our guide to going from Mounjaro to Wegovy explains what that process involves.

The honest summary: this is a manageable transition for many people, and the evidence base for tirzepatide is strong. Which medicine suits your situation is a clinical decision our prescribers make with you, not something that can be answered by a comparison page alone. If you'd like to explore the switch, check your eligibility with a free consultation and a real prescriber will review everything the same day.